This program has already taken place.
Immunotherapy Bridge • November 29 - 30, 2017
Melanoma Bridge • November 30 - December 2, 2016
Naples, Italy
Presented by Fondazione Melanoma Onlus in collaboration with the IRCCS Fondazione G. Pascale National Cancer Institute, Sidra Medical and Research Center, the Italian Association of Medical Oncology, and the Society for Immunotherapy of Cancer
Immunotherapy Bridge
The third annual Immunotherapy Bridge, which preceded Melanoma Bridge, is a scientific program focused on the application of immunotherapy, not only for melanoma, but also for cancer in general. The program lasted two days this year, to reflect the increasing importance of immunotherapy in clinical practice.
Attendees were expected from all around the world and were encouraged to submit their abstracts for poster or oral presentations during the event. All accepted abstracts were included in a scientific journal. The speaker of the abstracts selected for oral communication were exempt from the registration fee and will be invited as speakers to Naples.
New in 2017, SITC is collaboraed on a joint session at Immunotherapy Bridge on Evolving Topics in Cancer Immunotherapy:
Session Chair
Lisa H. Butterfield, PhD - University of Pittsburgh Medical Center Hillman Cancer Center
|
| |
|
| 9:30 - 9:50 a.m. |
DC Vaccine Combinations for Melanoma
Lisa H. Butterfield, PhD - University of Pittsburgh
|
| 9:50 - 10:10 a.m. |
The Next Generation of Oncolytic Viruses for the Treatment of Melanoma
Howard Kaufman, MD, FACS - Rutgers Cancer Institute of New Jersey
|
| 10:10 - 10:30 a.m. |
Neoantigens in Cancer Immunotherapy
Christopher A. Klebanoff, MD - Memorial Sloan Kettering Cancer Center
|
| 10:30 - 10:50 a.m. |
Next Generation Adoptive T Cell Therapy
Chrystal M. Paulos, PhD - Medical University of South Carolina
|
| 10:50 - 11:00 a.m. |
Discussion
|
| 11:00 - 11:15 a.m. |
Break |
| 11:15 a.m. - 12:15 p.m. |
Oral communications
|
| 12:15 - 1:15 p.m. |
Sponsored Symposium
|
| 1:15 -1:30 p.m. |
Conclusions
Session Chair |
For more information, visit www.melanomabridge.org.